Neoadjuvant Androgen Deprivation Therapy for Prostate Volume Reduction, Lower Urinary Tract Symptom Relief and Quality of Life Improvement in Men with Intermediate- to High-risk Prostate Cancer: A Randomised Non-inferiority Trial of Degarelix versus Goserelin plus Bicalutamide

Clinical Oncology

Volumn 25, Issue 3, 2013, Pages 190-196

  Mason, M ^a   Maldonado Pijoan, X ^b   Steidle, C ^c   Guerif, S ^d   Wiegel, T ^e   van der Meulen, E ^f   Bergqvist, P B F ^f   Khoo, V ^g  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Northeast Indiana Urology   (United States)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f Ferring Pharmaceuticals AS   (Denmark)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Prostate cancer; Prostate volume reduction; Short term androgen deprivation; Urinary symptom management

Indexed keywords

BICALUTAMIDE; DEGARELIX; GOSERELIN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FATIGUE; HOT FLUSH; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO; LOADING DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MALE; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE VOLUME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GOSERELIN; HUMANS; KALLIKREINS; MALE; NEOADJUVANT THERAPY; NITRILES; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; TESTOSTERONE; TOSYL COMPOUNDS;

EID: 84873078804     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.09.010     Document Type: Article

References (27)

1. Zietman A.L., Prince E.A., Nakfoor B.M., Park J.J. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997, 38:1067-1070.
2. Kumar S., Shelley M., Harrison C., Coles B., Wilt T.J., Mason M.D. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006, 18:CD006019.
3. Zelefsky M.J., Leibel S.A., Burman C.M., et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994, 29:755-761.
4. Henderson A., Langley S.E., Laing R.W. Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 2003, 15:318-321.
5. Pilepich M.V., Sause W.T., Shipley W.U., et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995, 45:616-623.
6. Roach M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591.
7. Denham J.W., Steigler A., Lamb D.S., et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459.
8. Van Poppel H. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res 2010, 2:39-52.
9. Sugiono M., Winkler M.H., Okeke A.A., Benney M., Gillatt D.A. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer - a pilot study. Prostate Cancer Prostatic Dis 2005, 8:91-94.
10. Gittelman M., Pommerville P.J., Persson B.E., Jensen J.K., Olesen T.K. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008, 180:1986-1992. Degarelix Study Group.
11. Payne H., Mason M. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011, 105:1628-1634.
12. Stone N.N., Marshall D.T., Stone J.J., Cesaretti J.A., Stock R.G. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?. J Urol 2010, 183:634-639.
13. Madersbacher S., Alivizatos G., Nordling J., Sanz C.R., Emberton M., de la Rosette J.J.E.A.U. 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004, 46:547-554.
14. Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008, 179:616-621.
15. Barry M.J., Williford W.O., Chang Y., et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol 1995, 154:1770-1774.
16. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001, 166:500-506.
17. Langenhuijsen J.F., van Lin E.N., Hoffmann A.L., et al. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol 2011, 29:52-57.
18. Ebara S., Manabe D., Kobayashi Y., et al. The efficacy of neoadjuvant androgen deprivation therapy as a prostate volume reduction before brachytherapy for clinically localized prostate cancer. Acta Med Okayama 2007, 61:335-340.
19. Sanghani M.V., Schultz D., Tempany C.M., et al. Quantifying the change in endorectal magnetic resonance imaging-defined tumor volume during neoadjuvant androgen suppression therapy in patients with prostate cancer. Urology 2003, 62:487-491.
20. Blank K.R., Whittington R., Arjomandy B., et al. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity. Cancer J Sci Am 1999, 5:370-373.
21. Kucway R., Vicini F., Huang R., Stromberg J., Gonzalez J., Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002, 167:2443-2447.
22. Axcrona K, Aaltomaa S, Martins da Silva C, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. Br J Urol Int http://dx.doi.org/10.1111/j.1464-410X.2012.11107.x.
23. Mommsen S., Petersen L. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J Urol Nephrol 1994, 28:401-404.
24. Klarskov L., Klarskov P., Mommsen S., Svoldgaard N. Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J Urol Nephrol 2012, 46:37-43.
25. Oesterling J.E. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia. J Androl 1991, 12:381-388.
26. Russo A., Castiglione F., Salonia A., et al. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats. Eur Urol 2011, 59:868-874.
27. Bono A.V., Salvadore M., Celato N. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol 2002, 24:221-227.